Mednet Logo
HomeRadiation OncologyQuestion

Would you treat an inoperable <5 cm NSCLC tumor involving the hilum with SBRT?

4
4 Answers
Mednet Member
Mednet Member
Radiation Oncology · Washington University School of Medicine

There is legitimate concern with the development of late toxicities such as bronchial stenosis and hemopytsis after SBRT for centrally located tumors. The recently updated data from RTOG 0813 confirms that even with early stage, node negative, centrally located tumors, there is an approximately 5% r...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · UCLA | VA Greater Los Angeles Healthcare System

Cliff's insights are invaluable, and a nice example of the incredible value that TheMedNet gives us to see what others are up to. The only additional value I can provide is to remind us that the shock-and-awe of 3-5 fraction SBRT was revealed to the world only through single-arm studies. It is for t...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · University of Washington School of Medicine

In RTOG 0813, the initial dose level 50 Gy in 5 fxs appears to be safe and I have not personally encountered problems with 50 Gy/ 5 fxs throughout these years. Having said that, serious complications are still possible. I share Cliff's concerns. Sometimes when the PTV is expanded into large airways ...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Cancer Care Centers of Brevard

Many would choose to treat this scenario with SBRT, but I believe chemo-radiation would be another alternative treatment choice if the patient is fit.

Register or Sign In to see full answer

Would you treat an inoperable <5 cm NSCLC tumor involving the hilum with SBRT? | Mednet